|
|
|
Volumn 14, Issue 4, 2004, Pages
|
|
Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
MONOCLONAL ANTIBODY;
PALIVIZUMAB;
CASE CONTROL STUDY;
COMPARATIVE STUDY;
CONGENITAL HEART MALFORMATION;
DRUG EFFECT;
FEMALE;
FOLLOW UP;
HUMAN;
INFANT;
MALE;
NEWBORN;
NOTE;
PRACTICE GUIDELINE;
REFERENCE VALUE;
RESPIRATORY SYNCYTIAL PNEUMOVIRUS;
RISK ASSESSMENT;
SENSITIVITY AND SPECIFICITY;
TREATMENT OUTCOME;
UNITED KINGDOM;
VIROLOGY;
VIRUS INFECTION;
ANTIBODIES, MONOCLONAL;
ANTIVIRAL AGENTS;
CASE-CONTROL STUDIES;
FEMALE;
FOLLOW-UP STUDIES;
GREAT BRITAIN;
HEART DEFECTS, CONGENITAL;
HUMANS;
INFANT;
INFANT, NEWBORN;
MALE;
PRACTICE GUIDELINES;
REFERENCE VALUES;
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;
RESPIRATORY SYNCYTIAL VIRUSES;
RISK ASSESSMENT;
SENSITIVITY AND SPECIFICITY;
TREATMENT OUTCOME;
|
|
EID: 20544438660
PISSN: 10479511
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
